Aura Biosciences reports Q2 2024 net loss of $20.3M; cash $187.4M into H2 2026

Aura Biosciences, Inc.

2024-Q2 EPS reported -$0.81

Net loss of $20.3M in Q2 2024 vs $18.3M in Q2 2023; R&D spend $16.9M, G&A $5.9M.
Cash and marketable securities $187.4M as of June 30, 2024; expected to fund operations into H2 2026.
Phase 3 CoMpass trial for small choroidal melanoma continues enrollment globally; target ~100 patients.
Early NMIBC Phase 1 data expected at virtual urologic oncology event in October 2024.
Phase 2 end-of-study data in small choroidal melanoma at Retina Society Annual Meeting Sept 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.